Kenvue Has Beat Estimates Four Straight Quarters While Analysts Keep Expecting Less

Kenvue Inc (KVUE) reports second-quarter earnings tomorrow, August 6, before market open, with analysts expecting steady growth from the consumer health giant. The central question is whether the company can extend its impressive streak of earnings beats—now four consecutive quarters—while navigating integration challenges and maintaining momentum across its Self Care, Skin Health and Beauty, and Essential Health segments. With the stock trading near analyst price targets and technical indicators flashing bullish signals, this report will test whether KVUE's operational execution can justify current valuations.

Part 1: Earnings Preview

Kenvue operates as a consumer health company across three segments—Self Care (cough, cold, allergy, pain care), Skin Health and Beauty (Neutrogena, OGX, Rogaine), and Essential Health (BAND-AID, Listerine, Johnson's)—selling over-the-counter medicines, personal care products, and wellness items globally. The company spun out from Johnson & Johnson in 2022 and has since established itself as a standalone consumer health leader with a portfolio of trusted household brands.

Kenvue reports second-quarter earnings on August 6 before market open, with analysts expecting EPS of $0.32 on revenue estimates around $3.97 billion. The company most recently reported first-quarter EPS of $0.32, which beat estimates of $0.27 by 18.52%. Compared to the same quarter last year when KVUE earned $0.29, the current consensus represents 10.34% year-over-year growth—a solid acceleration that reflects improving operational momentum.

Three key themes define this earnings story:

Integration and Standalone Execution: As a relatively young standalone entity, investors are watching how effectively KVUE operates independently from its former parent. The company faces ongoing integration challenges while establishing its own operational infrastructure, supply chain, and go-to-market strategies. Success here determines whether KVUE can maintain the efficiency and brand strength it inherited while building new capabilities.

Brand Portfolio Performance Across Segments: With iconic brands spanning multiple consumer health categories, segment-level performance will be critical. Investors want to see balanced growth across Self Care (which includes Tylenol and Benadryl), Skin Health and Beauty (led by Neutrogena), and Essential Health (featuring Listerine and BAND-AID). Any weakness in a major brand or category could signal competitive pressures or shifting consumer preferences.

Legal and Acquisition Overhang: Recent analysis highlights legal risks and uncertainty surrounding a planned acquisition by Kimberly-Clark. While the company has delivered consistent earnings beats, these external factors create uncertainty about KVUE's long-term strategic direction and could weigh on valuation regardless of quarterly operational performance.

Analyst commentary ahead of the release remains cautiously optimistic. The consensus holds at a neutral-to-slightly-bullish posture, with 12 of 13 analysts rating the stock a Hold and just one Strong Buy. The average price target of $19.67 sits exactly at the current trading price, suggesting analysts see the stock as fairly valued heading into the report. However, KVUE's track record of beating estimates—five consecutive quarters according to recent data—has built credibility with the Street and raised expectations for another positive surprise.

Part 2: Historical Earnings Performance

KVUE has established a clear pattern of exceeding analyst expectations, delivering positive earnings surprises in each of the past four reported quarters. The company beat estimates by 3.57% in June 2025, 3.70% in September 2025, then accelerated dramatically with a 22.73% beat in December 2025 and an 18.52% beat most recently in March 2026. This progression shows not just consistency but expanding outperformance—the two most recent quarters saw KVUE exceed expectations by significantly wider margins than earlier periods.

The trend suggests KVUE has either been conservative in guiding expectations or has genuinely improved operational execution as a standalone company. The December and March surprises were particularly impressive, with actual results coming in $0.05 and $0.06 above estimates respectively—substantial beats in absolute terms for a stock trading in the low-$20s range. This pattern has likely contributed to the stock's technical strength and may have set a high bar for tomorrow's release, as investors now anticipate continued outperformance rather than viewing beats as pleasant surprises.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

KVUE reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price behavior around earnings shows significant volatility, with an average absolute Day 0 move of 5.12% and Day 0 range of 4.88%. The most dramatic reaction came in November 2025, when the stock surged 12.32% on earnings day, though this was an outlier. More typical reactions include the May 2026 report (up 0.23%), February 2026 (down 1.55%), and August 2025 (up 1.49%)—suggesting investors should expect moves in the 1-3% range for a standard report.

Day +1 follow-through has been more muted, averaging 1.75% with a range of 2.86%, indicating most of the price discovery happens in the immediate reaction. Notably, several reports showed reversal patterns—the February 2026 report dropped 1.55% on Day 0 but recovered 2.55% on Day +1, while August 2025 gained 1.49% initially then gave back 1.93% the next session. This suggests traders should watch for potential mean reversion after the initial move, particularly if the Day 0 reaction is extreme.

Part 2.2: Options Market Expected Move

The options market is pricing a 1.99% expected move for this week's expiration, with an implied range of $19.27 to $20.05. This is substantially more conservative than KVUE's historical average earnings move of 5.12%, suggesting options traders expect a relatively calm reaction compared to past reports. The subdued implied volatility may reflect the stock's recent pattern of smaller moves (the May 2026 report moved just 0.23%) or could indicate complacency if KVUE delivers another significant surprise.

Part 3: What Analysts Are Saying

Analyst sentiment on KVUE is decidedly neutral, with the consensus rating at 3.15 (between Hold and Buy, closer to Hold) and an average price target of $19.67—exactly matching the current stock price. This suggests analysts view the stock as fairly valued with limited upside or downside from current levels. The target range spans $18.00 to $22.00, indicating some divergence in views but relatively tight clustering overall.

The rating breakdown shows 1 Strong Buy, 0 Moderate Buys, 12 Holds, and 0 Sells among 13 analysts covering the stock. This heavily Hold-weighted distribution reflects a wait-and-see posture, with most analysts wanting more evidence of standalone execution before upgrading. Notably, sentiment has deteriorated over the past month—the Strong Buy count dropped from 2 to 1, while Holds increased from 11 to 12, and the average recommendation declined from 3.31 to 3.15. This subtle downgrade suggests some analysts have grown more cautious, possibly due to valuation concerns, integration risks, or the acquisition uncertainty mentioned in recent analysis.

With the average price target implying essentially zero upside from the current $19.67 price, the analyst community is signaling that KVUE needs to deliver a strong earnings beat and raise guidance to justify further appreciation. The stock has already captured most of the value analysts see in the near term, making tomorrow's results and forward commentary critical for resetting expectations higher.

Part 4: Technical Picture

KVUE enters earnings with strong technical momentum, as the Barchart Technical Opinion shows a 100% Buy signal—unchanged from last week and up from 96% Buy a month ago. This consistent strength indicates the technical setup has been supportive throughout the recent period, with no deterioration as the earnings date approached.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the report
• Medium-term (100% Buy): Continued buy signal suggests the intermediate trend remains firmly positive
• Long-term (100% Buy): Buy signal across the longer timeframe confirms the overall uptrend is intact

Trend Characteristics: The signal strength is rated as Average with the Strongest direction, suggesting KVUE is in a well-established uptrend with clear directional conviction, though momentum indicators may not be at extreme levels.

The stock is trading above all major moving averages, including the 5-day ($19.36), 10-day ($19.40), 20-day ($19.22), 50-day ($18.65), 100-day ($18.02), and 200-day ($17.58). This complete alignment with the current price above every timeframe average is a textbook bullish configuration, indicating buyers have controlled the trend across all measured periods. The progressive stacking of moving averages—with shorter-term averages above longer-term ones—confirms the uptrend structure is healthy.

The 50-day moving average at $18.65 represents the nearest significant support level, about 5.2% below current prices, while the stock has built a cushion above its 200-day average of $17.58. With no overhead resistance from moving averages and the stock trading at analyst price targets, KVUE faces a technical setup that is supportive but leaves little room for disappointment—a strong beat could propel the stock to new highs, while a miss or weak guidance could trigger profit-taking back toward the $18.65-$19.22 support zone. The bullish technical picture suggests the path of least resistance remains higher, but the stock needs fundamental catalysts from tomorrow's report to extend gains beyond current levels.